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Background: Preclinical and clinical studies have shown for decades that tumor cells demonstrate significantly
enhanced sensitivity to “fever range” hyperthermia (increasing the intratumoral temperature to 42-45°C) than normal
cells, although it is unknown why cancer cells exhibit this distinctive susceptibility.
Methods: To address this issue, mammary epithelial cells and three malignant breast cancer lines were subjected to
hyperthermic shock and microarray, bioinformatics, and network analysis of the global transcription changes was
subsequently performed.
Results: Bioinformatics analysis differentiated the gene expression patterns that distinguish the heat shock response of
normal cells from malignant breast cancer cells, revealing that the gene expression profiles of mammary epithelial cells
are completely distinct from malignant breast cancer lines following this treatment. Using gene network analysis, we
identified altered expression of transcripts involved in mitotic regulators, histones, and non-protein coding RNAs as the
significant processes that differed between the hyperthermic response of mammary epithelial cells and breast cancer
cells. We confirmed our data via qPCR and flow cytometric analysis to demonstrate that hyperthermia specifically
disrupts the expression of key mitotic regulators and G2/M phase progression in the breast cancer cells.
Conclusion: These data have identified molecular mechanisms by which breast cancer lines may exhibit enhanced
susceptibility to hyperthermic shock.
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Although the effectiveness of standard therapies such as
surgery, chemotherapy, and irradiation has steadily im-
proved over the years, cancer remains one of the most
challenging problems of modern medicine. Among the
major issues that complicate cancer treatment is the fact
that cancerous cells are very difficult to therapeutically
target with any specificity as they are in many respects
similar to normal cells and have an astonishing ability of
“hiding” their peculiarities. It has been known for over
three decades that tumor cells demonstrate significantly* Correspondence: brad.bryan@ttuhsc.edu
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reproduction in any medium, provided the ormore sensitivity to mild hyperthermia in “fever-range”
temperatures (41-45°C) than normal cells [1,2]. Mild
hyperthermia has been shown in a wealth of preclinical
oncology studies to act as a dose modifying agent that in-
creases the therapeutic ratio of conventional therapy, thus
enhancing the effectiveness of a given dose without add-
itional toxicity [3]. Furthermore, numerous clinical trials
have combined hyperthermia with radiation therapy and/
or chemotherapy for many types of carcinomas (including
breast cancers) and sarcomas, and most studies have
shown a significant reduction in tumor volume when
hyperthermia is combined with standard treatments [4-7].
Various hyperthermia techniques have been developed to
treat breast cancer, including focused ultrasound [8], fo-
cused microwaves [9,10], and radiofrequency electric fields
[11]. Despite these techniques, various factors includingLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bution of heat specific to and throughout the entire tumor
mass. With the recent and rapid progression of nanobio-
technology applications in medicine, the development of
magnetic nanoparticles which can induce tumor hyperther-
mia through hysteresis loss in an alternating magnetic field
has renewed great interest in reexamining this adjuvant
therapy in tumor treatments [12]. Further development of
this technology may have the potential to overcome the pre-
vious limitations associated with older modalities of indu-
cing hyperthermia and lead to reduced morbidity and
mortality for patients.
Hyperthermia over a short period (generally 30 minutes
to 1 hour) has been shown to induce irreversible cell dam-
age and subsequent death in tumor cells, yet normal cells
are remarkably spared [1,2]. These effects are often very
rapid, with tumor apoptosis and necrosis occurring within
a short time (3–6 hrs) post heating [13]. Several mecha-
nisms have been proposed as to how hyperthermia kills
tumor cells including disruption of plasma membrane
protein and cytoskeletal distribution, altering mitochon-
drial membrane potential and cellular redox status, dis-
rupting cell cycle progression, inducing tumor hypoxia,
and affecting DNA damage repair mechanisms in the nu-
cleus [14-16], yet despite several decades of research the
definitive identification of mechanisms leading to the fa-
vorable clinical results of hyperthermia have not been
established. It has been further hypothesized that the
strong anti-tumor effect of hyperthermia may be due to
the low blood flow rate (and thus reduced dispersant cool-
ing following heating) found in the center of tumors due
to a disorganized and often dysfunctional vascular system.
Additionally, several reports indicate that hyperthermia
induces a strong immunological response via activation of
immune cells and sensitization of tumor cells to immune
effector cells [17-19]. Several studies have elucidated the
heat shock induced changes in global gene expression of
tumor cell lines such as squamous cell carcinoma, lymph-
oma, and glioma and have commonly identified gene net-
works involved in apoptosis, cell cycle, and cell structure/
maintanence [20-22]. However, none of these studies com-
pared the gene expression profiles to that of hyperthermia
treated normal cells, thus it remains unknown how the
hyperthermic response of cancer cells differs from that
of normal cells. Identification of the unique hyperthermia-
induced gene expression changes between normal and
cancer cells may not only shed light on the selective disad-
vantage of solid tumors in response to mild increases in
temperature, but could also identify signaling targets and
biological processes which potentially could be exploited
to sensitize tumors to chemotherapy and radiation.
To address this issue, we analyzed the hyperthermia-
induced global gene expression profiles of a panel of
breast cancer and mammary epithelial cell lines and usedbioinformatics analysis to identify the unique gene net-
works distinct between the normal and cancer lines fol-
lowing this treatment. Furthermore, we confirmed our
identified gene expression changes using qPCR and
utilized flow cytometry to verify that these transcriptional
alterations indeed reflect breast cancer specific responses
to hyperthermia.Methods
Cell culture and hyperthermia treatment
MCF10A (ATCC #CRL10318) mammary epithelial cells
and MCF7 luminal breast cancer cells (ATCC #HTB-22),
MDA-MB-231 Basal B breast cancer cells (ATCC #
HTB-26), and MDA-MB-468 Basal A breast cancer
cells (ATCC #HTB-132) were purchased from ATCC
and grown in standard culture conditions as previously
reported [23-25]. For heat shock, cells were split into
two groups: 37°C control (C and C’ for mammary epi-
thelial and breast cancer cells, respectively) and 45°C
hyperthermic treatment (H and H’ for mammary epi-
thelial and breast cancer cells, respectively). The 37°C
control was grown under standard culture conditions.
For the hyperthermia treatment, 45°C prewarmed condi-
tioned media was immediately added to each treatment
group and continuously maintained at this temperature
for 30 minutes. After this time, the 45°C media was com-
pletely removed and replaced with 37°C conditioned
media. The cells were then grown under standard culture
conditions and harvested at the time point indicated for
each experiment.Microarray analysis
Total RNA was collected from each cell line (triplicate
biological replicates) 4 hours after completion of the
hyperthermia treatment. RNA was amplified and biotin-
labeled using Illumina TotalPrep RNA Amplification Kit
(Ambion). 750 ng of biotinylated aRNA was then briefly
heat-denatured and loaded onto expression arrays to
hybridize overnight (triplicate technical replicates). Follow-
ing hybridization, arrays were labeled with Cy3-streptavidin
and imaged on the Illumina ISCAN. Intensity values were
transferred to GeneSpring GX microarray analysis software
(Agilent) and data was filtered based on quality of each call.
Statistical relevance was determined using ANOVA with a
Benjamini Hochberg FDR multiple testing correction
(p-value < 0.05). Data were then limited by fold change
analysis to statistically relevant data points demonstrating
a 2-fold or more change in expression. The microarray
data from this experiment is publically available on the
Gene Expression Omnibus (GEO Accession #GSE48398).
All heatmaps shown represent the combined average of all
biological and technical replicates.
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Pathway analysis to identify gene networks and biological
processes affected by the gene expression changes was
performed using Metacore software (Thomson Reuters).
Protein-protein interaction networks were determined
using String 9.05 (http://string-db.org).
Quantitative real time PCR analysis
RNA was isolated from cells 4 hours after the hyperthermia
treatment using the Ambion Purelink Minikit according to
the manufacturer’s directions. The RNA collected was from







































Figure 1 Fever range hyperthermic shock induces large-scale change
cells. (A) Heatmap depicting the 7252 two-fold or greater changes in gene
Hierarchical clustering based on cell lines shows the degree of similarity w
(red = overexpressed, green = underexpressed). (B) Venn diagram illustrating c
(p < 0.05) between each of the cell lines in the C vs H and C’ vs H’ compari
two-fold or greater gene expression change (p < 0.05) showing relative expRNA collected for the microarray to minimize the dis-
covery of false positives. qRT-PCR was performed on
an ABI7900HT RT-PCR system using TaqMan Assays
with predesigned primer sets for the genes of interest
(Invitrogen). All RT-PCR experiments were performed
in at least triplicate.
Flow cytometry
Cells were harvested 24 hours post treatment via trypsiniza-
tion and stained with propidium iodide as previous re-
ported [26]. Cell cycle profiles were independently obtained
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expression (p < 0.05) occurring in the C vs H and C’ vs H’ comparisons.
ith respect to gene expression clustering for each indicated cell line
ommon and unique 2-fold or greater gene expression changes
son. (C) Profile plot of the normalized intensity values for each
ression for each cell line in the in the C vs H and C’ vs H’ comparison.
Table 1 List of the top and bottom most regulated genes for each cell line in the C vs H and C’ vs H’ comparisons
Gene symbol Gene name Accession number MCF-10A MCF-7 MDA-231 MDA-468
MCF10A
XAGE1A X antigen family, member 1A, TV3 NM_001097593.1 64.0 1.2 1.0 122.0
XAGE1B X antigen family, member 1B, TV1 NM_001097595.1 60.3 1.2 1.1 131.6
SRGN Serglycin, TV1 NM_002727.2 58.1 1.1 −1.5 65.8
SRGN Serglycin, TV1 NM_002727.2 56.5 1.2 −1.5 67.7
LOC652683 Similar to sperm protein associated with the nucleus,
X chromosome, family member B1
XM_942283.2 50.0 1.2 −1.0 71.5
SPANXA2 SPANX family, member A2 NM_145662.2 49.3 1.2 −1.1 67.7
SPANXB1 SPANX family, member B1 NM_032461.2 48.7 1.2 −1.0 70.0
TOP2A Topoisomerase (DNA) II alpha 170 kDa NM_001067.2 39.0 −2.0 −3.7 1.1
LOC653219 Similar to G antigen, family D, 2 isoform 1a, TV1 XM_927237.1 37.0 1.2 1.1 71.8
LOC100133171 Hypothetical protein LOC100133171 XM_001713741.1 34.8 1.3 −1.1 52.7
RN5S9 RNA, 5S ribosomal 9 NR_023371.1 −48.2 11.5 59.7 11.5
RN7SK RNA, 7SK small nuclear NR_001445.1 −55.1 13.1 45.4 38.6
SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin),
member 5
NM_002639.3 −65.8 1.2 7.6 −3.8
KIAA1666 KIAA1666 protein XM_942124.2 −72.9 17.9 33.4 35.3
AKR1C2 Aldo-keto reductase family 1, member C2, TV1 NM_001354.4 −82.3 1.4 24.4 −9.6
LOC650517 Hypothetical LOC650517 XR_019109.1 −90.0 1.2 1.7 −2.0
RN7SK RNA, 7SK small nuclear NR_001445.1 −109.9 20.2 62.1 45.2
KRT17P3 Predicted misc_RNA KRT17P3 XR_015626.2 −133.2 1.5 2.6 −4.5
LOC651397 Predicted misc_RNA LOC651397 XR_037048.1 −141.4 1.2 5.1 −4.1
KRT6A Keratin 6A NM_005554.3 −242.8 1.2 116.7 −11.7
MCF7
RNY5 RNA, Ro-associated Y5 NR_001571.2 −17.4 22.6 4.6 4.3
RN7SK RNA, 7SK small nuclear NR_001445.1 −109.9 20.2 62.1 45.2
KIAA1666 KIAA1666 protein XM_942124.2 −72.9 17.9 33.4 35.3
MIR1974 MicroRNA 1974 NR_031738.1 −9.4 14.2 20.8 133.3
LOC100008589 28S ribosomal RNA NR_003287.1 −26.8 13.8 26.4 113.8
RN7SK RNA, 7SK small nuclear NR_001445.1 −55.1 13.1 45.4 38.6
LOC100132394 Hypothetical protein LOC100132394 XM_001713809.1 −19.4 12.3 22.2 105.0
RNU4-1 RNA, U4 small nuclear 1 NR_003925.1 −7.7 11.5 11.4 13.2
RN5S9 RNA, 5S ribosomal 9 NR_023371.1 −48.2 11.5 59.7 11.5
SNORD3C Small nucleolar RNA, C/D box 3C NR_006881.1 −34.9 11.1 30.5 11.8
CCDC117 Coiled-coil domain containing 117 NM_173510.1 3.2 −3.3 −1.7 −1.8
LOC730432 Hypothetical protein LOC730432 XM_001125680.1 3.7 −3.3 −1.3 −4.7
LOC644799 Hypothetical protein LOC644799, TV1 XM_934554.1 2.5 −3.3 −2.1 1.1
RPS6KB1 Ribosomal protein S6 kinase, 70 kDa, polypeptide 1 NM_003161.2 2.9 −3.4 −1.8 −3.7
NRIP1 Nuclear receptor interacting protein 1 NM_003489.2 1.1 −3.4 −1.8 −4.2
AP4E1 Adaptor-related protein complex 4, epsilon 1 subunit NM_007347.3 2.3 −3.4 −2.1 −2.2
DCP2 DCP2 decapping enzyme homolog (S. cerevisiae), TV1 NM_152624.4 3.1 −3.4 −2.4 −6.8
TROVE2 TROVE domain family, member 2, TV1 NM_001042369.1 2.0 −3.8 −1.2 −8.2
PURB Purine-rich element binding protein B NM_033224.3 3.2 −3.8 −2.6 −7.1
ZNF217 Zinc finger protein 217 NM_006526.2 3.2 −3.9 −1.7 −2.5
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Table 1 List of the top and bottom most regulated genes for each cell line in the C vs H and C’ vs H’ comparisons
(Continued)
MDA231
KRT6A Keratin 6A NM_005554.3 −242.8 1.2 116.7 −11.7
RN7SK RNA, 7SK small nuclear NR_001445.1 −109.9 20.2 62.1 45.2
RN5S9 RNA, 5S ribosomal 9 NR_023371.1 −48.2 11.5 59.7 11.5
RN7SK RNA, 7SK small nuclear NR_001445.1 −55.1 13.1 45.4 38.6
SNORD3D Small nucleolar RNA, C/D box 3D NR_006882.1 −47.2 11.1 36.8 9.4
SNORD3A Small nucleolar RNA, C/D box 3A NR_006880.1 −46.0 11.1 36.5 9.0
KIAA1666 KIAA1666 protein XM_942124.2 −72.9 17.9 33.4 35.3
SNORD3C Small nucleolar RNA, C/D box 3C NR_006881.1 −34.9 11.1 30.5 11.8
LOC100008589 28S ribosomal RNA NR_003287.1 −26.8 13.8 26.4 113.8
LOC100132564 Hypothetical protein LOC100132564 XM_001713808.1 −21.6 8.4 25.3 13.3
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 NM_002577.3 5.9 −2.9 −3.1 −1.3
CEP55 Centrosomal protein 55 kDa, TV1 NM_018131.3 19.2 −1.7 −3.2 −1.2
RHOBTB3 Rho-related BTB domain containing 3 NM_014899.3 14.0 −1.1 −3.2 2.5
ZAK Sterile alpha motif and leucine zipper containing kinase AZK, V2 NM_133646.2 2.8 −2.6 −3.2 −4.0
KATNAL1 Katanin p60 subunit A-like 1, TV2 NM_001014380.1 3.6 −1.4 −3.2 −1.3
PBK PDZ binding kinase NM_018492.2 10.5 −1.9 −3.3 −1.0
PAFAH1B1 Platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit NM_000430.2 4.5 −2.6 −3.5 1.2
TOP2A Topoisomerase (DNA) II alpha 170 kDa NM_001067.2 39.0 −2.0 −3.7 1.1
FAM83D Family with sequence similarity 83, member D NM_030919.2 15.4 −1.8 −4.0 −1.7
BCAT1 Branched chain aminotransferase 1, cytosolic NM_005504.4 8.9 1.1 −4.9 2.9
MDA468
MIR1974 microRNA 1974 NR_031738.1 −9.4 14.2 20.8 133.3
XAGE1B X antigen family, member 1B, TV1 NM_001097595.1 60.3 1.2 1.1 131.6
XAGE1A X antigen family, member 1A, TV3 NM_001097593.1 64.0 1.2 1.0 122.0
LOC100008589 28S ribosomal RNA NR_003287.1 −26.8 13.8 26.4 113.8
LOC100132394 Hypothetical protein LOC100132394 XM_001713809.1 −19.4 12.3 22.2 105.0
CST3 Cystatin C NM_000099.2 −1.8 1.2 1.7 103.9
ACTG1 Actin, gamma 1 NM_001614.2 1.1 1.5 1.5 75.2
LOC653219 Similar to G antigen, family D, 2 isoform 1a, XM_927237.1 37.0 1.2 1.1 71.8
LOC652683 Similar to sperm protein associated with the nucleus,
X chromosome, family member B1
XM_942283.2 50.0 1.2 −1.0 71.5
SPANXB1 SPANX family, member B1 NM_032461.2 48.7 1.2 −1.0 70.0
CSAG1 Chondrosarcoma associated gene 1, TVb NM_153479.1 1.7 1.2 −1.0 −27.4
SERPINA3 Serpin peptidase inhibitor,
clade A (alpha-1 antiproteinase, antitrypsin), member 3
NM_001085.4 −8.5 1.1 2.0 −30.5
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 NM_000693.1 −1.5 −1.0 2.0 −34.0
EPCAM Epithelial cell adhesion molecule NM_002354.2 1.6 −1.2 −1.2 −36.1
LAD1 Ladinin 1 NM_005558.3 −47.9 1.2 13.5 −37.5
OLFML3 Olfactomedin-like 3 NM_020190.2 −1.2 1.2 1.2 −39.0
TACSTD1 Tumor-associated calcium signal transducer 1 NM_002354.1 2.1 −1.1 −1.4 −47.5
RARRES1 Retinoic acid receptor responder (tazarotene induced) 1, TV1 NM_206963.1 −1.3 1.3 −1.1 −49.9
MGP Matrix Gla protein NM_000900.2 −18.6 1.0 2.4 −51.1
KLK5 Kallikrein-related peptidase 5, TV1 NM_012427.4 −1.3 1.1 1.1 −56.3











































































































































































































Figure 2 Mammary epithelial cells respond to fever range hyperthermia through transcriptional alterations in gene networks unique
from that of breast cancer cells. Hierarchical clustered heatmaps depicting the transcriptional expression changes for genes involved in cell
cycle (A), apoptosis (B), heatshock (C), DNA damage (D), and Ran/Rab (E) regulation in the C vs H and C’ vs H’ comparison (red = overexpressed,
green = underexpressed).
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Table 2 List of genes involved in the gene networks that are differentially regulated between mammary epithelial cells
in the (C vs H and C’ vs H’) comparison
Gene symbol Gene name Accession number MCF-10A MCF-7 MDA-231 MDA-468
DNA Damage
USP1 Ubiquitin specific peptidase 1, TV3 NM_001017416.1 4.8 −1.8 −2.2 −5.3
CDC25A Cell division cycle 25A, TV1 NM_001789.2 4.6 −1.3 1.2 2.0
BARD1 BRCA1 associated RING domain 1 NM_000465.1 3.5 −1.7 −2.8 −1.7
MDC1 Mediator of DNA-damage checkpoint 1 NM_014641.1 3.0 −1.4 1.1 −1.2
NBN Nibrin NM_002485.4 2.5 −2.4 −2.2 −1.1
SLC35B2 Solute carrier family 35, member B2 NM_178148.1 2.3 −1.0 1.8 1.8
CHEK1 Checkpoint kinase 1, TV3 NM_001274.3 2.3 −1.1 −1.4 −2.6
CCNE1 Cyclin E1, TV2 NM_057182.1 2.1 −1.2 −1.1 −1.0
CCNA1 Cyclin A1, TV1 NM_003914.2 −2.2 1.2 1.0 −1.3
GADD45B Growth arrest and DNA-damage-inducible, beta NM_015675.2 −3.8 1.1 1.8 −1.1
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1), TV1 NM_000389.2 −4.7 1.1 2.5 1.1
Cell Cycle
AURKA Aurora kinase A, TV5 NM_198436.1 22.0 −1.3 −2.1 1.2
CDC20 Cell division cycle 20 NM_001255.2 18.0 1.1 −1.1 −1.2
CCNB2 Cyclin B2 NM_004701.2 17.5 −1.3 −2.3 −1.1
NCAPG Non-SMC condensin I complex, subunit G, TV1 NM_022346.3 14.9 −1.4 −2.6 −1.1
BUB1 Budding uninhibited by benzimidazoles 1 homolog (yeast) NM_004336.2 10.8 −1.5 −2.3 1.2
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) NM_002358.2 9.8 −1.5 −1.6 2.1
CDC45L Cell division cycle 45, TV2 NM_003504.3 8.0 1.1 1.4 1.1
CENPF Centromere protein F, 350/400 kDa NM_016343.3 7.8 −1.3 −3.0 1.1
PTTG1 Pituitary tumor-transforming 1 NM_004219.2 7.2 1.0 −1.0 1.4
MCM3 Minichromosome maintenance complex component 3, TV1 NM_002388.3 7.2 −1.5 −1.1 −1.4
CCNB1 Cyclin B1 NM_031966.2 6.9 −1.2 −2.5 1.1
CENPE Centromere protein E, 312 kDa NM_001813.2 6.6 −1.4 −2.5 −1.5
KIF11 Kinesin family member 11 NM_004523.2 6.5 −1.4 −2.7 −1.0
NDC80 NDC80 kinetochore complex component NM_006101.1 6.5 −1.1 −1.8 1.4
XPO1 Exportin 1 (CRM1 homolog, yeast) NM_003400.3 6.1 −2.7 −2.4 −3.0
RFC5 Replication factor C (activator 1) 5, 36.5 kDa, TV1 NM_007370.3 5.8 −1.2 −1.1 1.7
POLA1 Polymerase (DNA directed), alpha 1, catalytic subunit NM_016937.2 5.7 −1.5 −1.8 −1.2
RFC4 Replication factor C (activator 1) 4, 37 kDa, TV2 NM_181573.1 5.6 −1.2 −1.4 −1.4
CDC2 Cyclin-dependent kinase 1, TV1 NM_001786.2 5.2 −1.2 −2.3 1.7
CENPA Centromere protein A, TV2 NM_001042426.1 4.9 −1.3 −1.7 1.3
CKS1B CDC28 protein kinase regulatory subunit 1B, TV1 NM_001826.1 4.8 −1.2 −1.3 1.6
DSN1 MIND kinetochore complex component, TV3 NM_024918.2 4.7 −1.3 −1.8 −1.1
CDC25A Cell division cycle 25A, TV1 NM_001789.2 4.6 −1.3 1.2 2.0
NUF2 NDC80 kinetochore complex component, TV2 NM_031423.3 4.3 1.0 −2.0 1.7
PPP2CA Protein phosphatase 2, catalytic subunit, alpha isozyme NM_002715.2 4.3 −1.8 −2.0 −2.6
PRIM1 Primase, DNA, polypeptide 1 (49 kDa) NM_000946.2 4.2 1.0 −1.0 1.8
YWHAH Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, eta polypeptide
NM_003405.3 4.0 −1.9 −1.6 −3.9
TUBB Tubulin, beta class I NM_178014.2 3.9 −1.1 1.3 1.9
STAG2 Stromal antigen 2, TV2 NM_001042750.1 3.9 −2.8 −2.4 −3.4
CSE1L CSE1 chromosome segregation 1-like (yeast), TV2 NM_177436.1 3.8 −1.4 −1.6 1.3
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Table 2 List of genes involved in the gene networks that are differentially regulated between mammary epithelial cells
in the (C vs H and C’ vs H’) comparison (Continued)
MCM6 Minichromosome maintenance complex component 6 NM_005915.4 3.8 −1.3 −1.4 −3.4
RPA1 Replication protein A1, 70 kDa NM_002945.2 3.7 −1.3 −1.2 1.1
TOP2B Topoisomerase (DNA) II beta 180 kDa NM_001068.2 3.7 −2.5 −2.6 −2.0
RALA V-ral simian leukemia viral oncogene homolog A (ras related) NM_005402.2 3.6 −1.7 −1.6 −2.3
SPC25 SPC25, NDC80 kinetochore complex component NM_020675.3 3.6 −1.1 −1.4 1.4
MAPK13 Mitogen-activated protein kinase 13, TV1 NM_002754.3 3.6 1.1 1.3 −1.2
RPA3 Replication protein A3, 14 kDa NM_002947.3 3.5 −1.2 −1.1 −1.3
E2F3 E2F transcription factor 3, TV1 NM_001949.2 3.5 −2.0 −2.2 −4.5
MCM10 Minichromosome maintenance complex component 10, TV2 NM_018518.3 3.4 −1.2 −1.2 2.3
NEK2 NIMA-related kinase 2, TV1 NM_002497.2 3.4 −1.1 −2.1 1.1
MAP2K4 Mitogen-activated protein kinase kinase 4 NM_003010.2 3.3 −2.3 −2.5 −3.1
DYNC1H1 Dynein, cytoplasmic 1, heavy chain 1 NM_001376.2 3.3 −2.1 −1.1 1.2
KIF22 Kinesin family member 22, TV1 NM_007317.1 3.2 −1.1 −1.1 1.1
RPA2 Replication protein A2, 32 kDa NM_002946.3 3.2 −1.0 1.0 1.4
CDC7 Cell division cycle 7, TV1 NM_003503.2 3.2 −1.3 −1.8 −3.1
RBL1 Retinoblastoma-like 1 (p107), TV1 NM_002895.2 3.2 −1.1 −2.0 1.4
MCM5 Minichromosome maintenance complex component 5 NM_006739.3 3.1 1.1 1.8 1.8
TGFB2 Transforming growth factor, beta 2 NM_003238.1 3.0 1.2 −1.4 1.7
E2F2 E2F transcription factor 2 NM_004091.2 3.0 −1.7 1.2 −3.7
CDCA1 Cell division cycle associated 1, TV1 NM_145697.1 3.0 1.1 −2.3 1.9
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12), TV1
NM_002211.2 3.0 −1.7 −1.2 1.4
MCM2 Minichromosome maintenance complex component 2, TV1 NM_004526.2 3.0 1.0 1.7 1.8
RFC3 Replication factor C (activator 1) 3, 38 kDa, TV1 NM_002915.3 2.9 −1.7 −1.8 −2.2
NEDD8 Neural precursor cell expressed, developmentally down-regulated 8 NM_006156.2 2.9 −1.1 −1.0 1.4
BIRC5 Baculoviral IAP repeat containing 5, TV3 NM_001012271.1 2.9 −1.1 −1.4 1.2
RPS6KB1 Ribosomal protein S6 kinase, 70 kDa, polypeptide 1, TV1 NM_003161.2 2.9 −3.4 −1.8 −1.2
KPNA4 Karyopherin alpha 4 (importin alpha 3) NM_002268.3 2.8 −1.3 −2.1 −1.1
PPP1CB Protein phosphatase 1, catalytic subunit, beta isozyme, TV3 NM_206876.1 2.7 −2.6 −2.9 −1.1
PLK1 Polo-like kinase 1 NM_005030.3 2.7 1.1 −1.1 1.2
CDK6 Cyclin-dependent kinase 6, TV1 NM_001259.5 2.7 −1.5 −2.9 2.1
NEK6 NIMA-related kinase 6, TV2 NM_014397.3 2.7 1.1 −1.2 1.1
KPNB1 Karyopherin (importin) beta 1, TV1 NM_002265.4 2.7 −1.2 −1.2 1.1
RAD21 RAD21 homolog (S. pombe) NM_006265.1 2.7 −1.7 −1.7 1.4
DSCC1 Defective in sister chromatid cohesion 1 NM_024094.1 2.7 −1.6 −1.6 −1.4
TNPO1 Transportin 1, TV2 NM_153188.2 2.7 −1.6 −2.4 1.1
YWHAB Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta polypeptide, TV1
NM_003404.3 2.6 1.1 −1.1 −1.5
TUBG1 Tubulin, gamma 1 NM_001070.3 2.6 1.0 −1.0 −1.0
FBXW11 F-box and WD repeat domain containing 11, TV1 NM_033645.2 2.6 −2.3 −2.3 1.4
BUB3 Budding uninhibited by benzimidazoles 3 homolog (yeast), TV2 NM_001007793.1 2.6 1.1 −1.1 −3.0
TUBA1B Tubulin, alpha 1b NM_006082.2 2.6 1.1 1.2 1.7
DYNC1LI2 Dynein, cytoplasmic 1, light intermediate chain 2 NM_006141.2 2.6 −2.5 −1.5 −1.2
TUBB2A Tubulin, beta 2A class IIa NM_001069.2 2.5 1.3 1.5 −1.4
CHUK Conserved helix-loop-helix ubiquitous kinase NM_001278.3 2.5 −1.9 −2.1 1.7
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Table 2 List of genes involved in the gene networks that are differentially regulated between mammary epithelial cells
in the (C vs H and C’ vs H’) comparison (Continued)
IPO5 Importin 5 NM_002271.4 2.5 −1.2 −2.0 1.3
RAN RAN, member RAS oncogene family NM_006325.2 2.5 −1.4 −1.5 1.6
RASSF1 Ras association (RalGDS/AF-6) domain family member 1, TVA NM_007182.4 2.5 1.2 1.4 −1.1
INCENP Inner centromere protein antigens 135/155 kDa, TV1 NM_001040694.1 2.5 −1.2 −1.2 2.0
DYNLT3 Dynein, light chain, Tctex-type 3 NM_006520.1 2.5 −1.3 −1.8 1.7
NCAPD3 Non-SMC condensin II complex, subunit D3 NM_015261.2 2.5 −1.1 1.2 −2.6
YWHAQ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, theta polypeptide
NM_006826.2 2.5 −1.2 −1.4 1.8
TFDP1 Transcription factor Dp-1, TV1 NM_007111.3 2.4 −1.4 −1.5 −3.9
PDS5A PDS5, regulator of cohesion maintenance, TV2 NM_015200.1 2.4 −2.4 −2.1 1.9
MIS12 MIS12, MIND kinetochore complex component, TV2 NM_024039.1 2.4 −1.5 −1.5 −3.4
CDC23 Cell division cycle 23 NM_004661.3 2.4 −1.3 −1.2 1.3
POLS PAP associated domain containing 7, TV1 NM_006999.3 2.4 −1.8 −1.5 −3.4
CDC25C Cell division cycle 25C, TV1 NM_001790.3 2.3 1.1 1.1 1.1
BUB1B BUB1 mitotic checkpoint serine/threonine kinase B NM_001211.4 2.3 −1.1 −1.4 −2.0
ANAPC11 Anaphase promoting complex subunit 11, TV4 NM_001002246.1 2.3 1.1 1.1 −2.3
CHEK1 Checkpoint kinase 1, TV3 NM_001274.3 2.3 −1.1 −1.4 1.4
ZW10 Zw10 kinetochore protein NM_004724.2 2.3 −1.4 −1.9 −1.2
SMC2 Structural maintenance of chromosomes 2, TV1 NM_001042550.1 2.3 −1.6 −1.8 −1.3
CUL1 Cullin 1 NM_003592.2 2.3 −1.6 −1.8 −4.5
TUBA1C Tubulin, alpha 1c NM_032704.3 2.2 1.0 1.0 2.3
SMC4 Structural maintenance of chromosomes 4, TV2 NM_001002800.1 2.2 1.4 −2.0 1.1
CAPZA2 Capping protein (actin filament) muscle Z-line, alpha 2 NM_006136.2 2.2 −2.0 −1.3 −3.1
PCNA Proliferating cell nuclear antigen NM_182649.1 2.1 −1.1 −1.4 1.2
PPP2R5C Protein phosphatase 2, regulatory subunit B',
gamma isoform , TV4
NM_178588.1 2.1 −1.0 −1.2 1.1
SKP1A S-phase kinase-associated protein 1, TV1 NM_006930.2 2.1 −1.4 −1.8 1.4
TGFBR2 Transforming growth factor, beta receptor II (70/80 kDa), TV1 NM_001024847.1 2.1 −1.5 −1.8 −3.1
CHTF18 CTF18, chromosome transmission fidelity factor 18 NM_022092.1 2.1 −1.1 1.3 1.4
CCNE1 Cyclin E1, TV2 NM_057182.1 2.1 −1.2 −1.1 1.8
YWHAZ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide
NM_003406.2 2.1 −1.6 −1.6 1.7
CCT8 Chaperonin containing TCP1, subunit 8 (theta) NM_006585.2 2.1 −1.3 −1.8 −3.7
TUBB4Q Tubulin, beta polypeptide 4, member Q, pseudogene NM_020040.3 2.1 −1.0 1.2 1.9
WEE1 WEE1 homolog (S. pombe), TV1 NM_003390.2 2.1 −1.7 −2.2 1.4
RB1 Retinoblastoma 1 NM_000321.2 2.0 −1.4 −1.7 1.8
PPP2R5B Protein phosphatase 2, regulatory subunit B', beta NM_006244.2 −2.0 −1.0 1.2 −2.2
CCNA1 Cyclin A1, TV1 NM_003914.2 −2.2 1.2 1.0 1.4
TOB1 Transducer of ERBB2, 1, TV1 NM_005749.2 −2.3 −1.3 −1.4 1.2
LIMK2 LIM domain kinase 2, TV1 NM_001031801.1 −2.3 1.2 1.5 −1.2
MYL5 Myosin, light chain 5, regulatory NM_002477.1 −2.5 1.3 1.5 −1.1
TP63 Tumor protein p63, TV5 NM_001114981.1 −3.8 −1.1 3.7 −1.1
JUNB Jun B proto-oncogene NM_002229.2 −4.3 −1.2 1.6 1.2
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha), TV1 NM_181523.1 −4.7 −2.1 1.7 2.1
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) NM_000389.2 −4.7 1.1 2.5 1.1
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Table 2 List of genes involved in the gene networks that are differentially regulated between mammary epithelial cells
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RAC1 Ras-related C3 botulinum toxin substrate 1 (rho family,
small GTP binding protein Rac1), Rac1b
NM_018890.2 −7.6 −1.0 1.6 1.1
FOS FBJ murine osteosarcoma viral oncogene homolog NM_005252.2 −14.9 1.0 2.4 1.4
Apoptosis
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 NM_002577.3 6.0 −2.9 −3.1 −1.3
CDC2 Cyclin-dependent kinase 1, TV1 NM_001786.2 5.2 −1.2 −2.3 1.7
BARD1 BRCA1 associated RING domain 1 NM_000465.1 3.5 −1.7 −2.8 −1.7
MAP2K4 Mitogen-activated protein kinase kinase 4 NM_003010.2 3.3 −2.3 −2.5 −3.1
MAP3K4 Mitogen-activated protein kinase kinase kinase 4, TV1 NM_005922.2 2.6 −1.6 −2.2 −2.5
MAP3K1 Mitogen-activated protein kinase kinase kinase 1,
E3 ubiquitin protein ligase
NM_005921.1 2.6 −2.4 −1.6 −3.8
BIRC2 Baculoviral IAP repeat containing 2, TV1 NM_001166.3 2.6 −1.4 −2.1 1.5
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 NM_021627.2 2.5 −1.7 −1.8 −1.6
RIPK1 Receptor (TNFRSF)-interacting serine-threonine kinase 1 NM_003804.3 2.5 −1.7 −2.1 −4.5
YWHAQ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, theta polypeptide
NM_006826.2 2.5 −1.2 −1.4 −2.1
MAPK9 Mitogen-activated protein kinase 9, TV JNK2-a2 NM_002752.3 2.4 −1.3 −1.5 −2.5
CASP3 Caspase 3, apoptosis-related cysteine peptidase, TV beta NM_032991.2 2.2 −1.3 −1.7 −4.0
APAF1 Apoptotic peptidase activating factor 1, TV1 NM_013229.2 2.2 −1.5 −1.4 −2.0
BMF Bcl2 modifying factor, TV2 NM_033503.3 −2.0 1.0 1.1 −1.2
CFLAR CASP8 and FADD-like apoptosis regulator NM_003879.3 −2.3 1.2 1.1 −1.9
HSPB1 Heat shock 27 kDa protein 1 NM_001540.2 −2.7 1.2 1.5 −1.1
GADD45B Growth arrest and DNA-damage-inducible, beta NM_015675.2 −3.8 1.1 1.8 −1.1
TNFRSF6B Tumor necrosis factor receptor superfamily, member 6b,
decoy, transcript variant M68C
NM_032945.2 −4.3 −1.0 1.2 1.8
Heat Shock
HSP90AA1 Heat shock protein 90 kDa, class A member 1 NM_001017963.2 4.0 −1.4 −1.7 1.1
CARHSP1 Calcium regulated heat stable protein 1, 24 kDa NM_001042476.1 3.2 1.0 1.1 −1.1
HSPA12A Heat shock protein 70 kDa 12A NM_025015.2 2.3 −1.2 −1.7 1.4
HSPB1 Heat shock protein 27 kDa protein 1 NM_001540.2 −2.7 1.2 1.5 −1.1
HSPBL2 Heat shock 27 kDa protein 1 pseudogene 1 NR_024392.1 −3.2 1.2 1.6 −1.0
HSPA6 Heat shock 70 kDa protein 6 NM_002155.3 −5.3 1.2 1.1 1.3
HSPA7 Heat shock 70 kDa protein 7 NR_024151.1 −4.0 1.2 1.4 1.2
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FlowJo software (Tree Star) or CFlow Plus software
(Accuri).
Results
Determination of the global transcriptional response of
mammary epithelial and breast cancer cells to fever
range hyperthermia
It remains to be determined how mild hyperthermia
preferentially selects against breast cancer cells, yet largely
spares normal tissue from collateral damage. To address
this question, we first sought to elucidate how hyperther-
mia induces alterations in gene expression patterns in
mammary epithelial and breast cancer cells. Mammaryepithelial cells (MCF10A) and three malignant breast
cancer lines from each of the known subtypes (MCF7
[luminal], MDA231 [Basal B], and MDA468 [Basal A])
were subjected to 30 minutes of fever range hyperthermic
shock (or maintained at 37°C as a control) as described in
the Materials and Methods section. To streamline identifi-
cation of these treatment groups, cells grown at 37°C will
be referred to as C and C’ (for mammary epithelial and
breast cancer cells, respectively), while cells grown at 45°C
will be referred to as H and H’ (for mammary epithelial
and breast cancer cells, respectively). Total RNA was iso-
lated 4 hours following hyperthermic treatment. We then
performed microarray analysis of the global transcription
changes using Illumina high density BeadArrays which
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transcripts and known splice variants across the human
transcriptome. Data was filtered based on quality of
each call and statistical relevance was determined using
ANOVA with a Benjamini Hochberg FDR multiple testing
correction (p-value < 0.05). Data were then limited by fold
change analysis to statistically relevant data points demon-
strating a 2-fold or more change in expression. When
comparing the expression changes based on the C vs H
and C’ vs H’ analysis, we discovered that hyperthermia
induced very dramatic changes in gene expression in all
cell lines tested as reflected by 7252 two-fold or greater
statistically significant gene expression changes (p < 0.05)
occurring in at least one of the four cell lines (Figure 1A).
Specifically, hyperthermia significantly altered the expres-
sion of 2670 genes in the MCF10A line (1810 genes upreg-
ulated and 860 genes downregulated), 442 genes in MCF7
















Figure 3 Identification of genes that differentiate the transcriptional res
(A) Heatmap depicting the two-fold or greater changes in gene expression (p
MDA231, MDA468) relative to the mammary epithelial cells in the H’ vs H com
illustrating common and unique 2-fold or greater gene expression changes (p
relative to the mammary epithelial cells in the H’ vs H comparison.genes in MDA231 (244 genes upregulated and 371 down-
regulated), and 4458 genes in MDA468 (1744 genes up-
regulated and 2714 genes downregulated). A list of the top
and bottom most regulated genes for each cell line can be
found in Table 1. The complete gene expression dataset
has been freely and publically deposited in Gene Expres-
sion Omnibus for ease of access and meta-analysis (GEO
Accession #48398). These data suggest that mild hyper-
thermia induces large-scale alterations in gene expression
profiles across normal and breast cancer cell lines.
Hierarchical clustering of the gene expression changes
based on each cell line indicates that the breast cancer
lines responded to hyperthermia more similarly to each
other than to the mammary epithelial line (Figure 1A).
Using a Venn diagram that strictly eliminated any genes
with less than a 2-fold expression change (p < 0.05), we
compared the gene expression profiles that were shared









ponse of breast cancer cells following fever range hyperthermia.
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parison (red = overexpressed, green = underexpressed). (B) Venn diagram
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Table 3 List of genes that statistically distinguish the hyperthermic response of three breast cancer lines from the
mammary epithelial cells in the H’ vs H analysis
Gene Symbol Gene Name Accession Number MCF-7 MDA-231 MDA-468
RN7SK RNA, 7SK small nuclear NR_001445.1 68.5 64.5 73.5
RN5S9 RNA, 5S ribosomal 9 NR_023371.1 54.5 64.7 64.9
RNU1-3 RNA, U1 small nuclear 3 NR_004408.1 44.2 27.9 30.3
RNU1G2 RNA, U1 small nuclear 4 NR_004426.1 42.5 26.4 28.5
KIAA1666 RIMS binding protein 3 XM_942124.2 38.5 36.1 41.6
RNU1-5 RNA, U1 small nuclear 5 NR_004400.1 36.5 25.1 28.1
SNORD3D Small nucleolar RNA, C/D box 3D NR_006882.1 34.8 43.3 47.2
RNU1A3 RNA, U1 small nuclear 1 NR_004430.1 30.2 19.9 20.3
SNORD3A Small nucleolar RNA, C/D box 3A NR_006880.1 30.1 42.6 43.8
SNORD3C Small nucleolar RNA, C/D box 3C NR_006881.1 28.4 30.9 34.7
RNY5 RNA, Ro-associated Y5 NR_001571.2 27.8 4.6 4.3
LOC100008589 RNA28S5 RNA, 28S ribosomal 5 NR_003287.1 27.2 28.9 30.9
LOC100132564 Hypothetical Protein LOC100132564 XM_001713808.1 26.7 26.5 27.3
LOC100132394 Hypothetical Protein XP_001713861.1 23.8 23.1 22.9
RNU4-1 RNA, U4 small nuclear 1 NR_003925.1 18.5 11.6 13.1
RNU6ATAC RNA, U6atac small nuclear (U12-dependent splicing) NR_023344.1 16.3 11.8 12.4
LOC100134364 Hypothetical Protein LOC100134364 XM_001713810.1 15.9 15.5 17.2
HIST2H2AA3 Histone cluster 2, H2aa3 NM_003516.2 15.3 3.2 3.1
HIST2H2AA4 Histone cluster 2, H2aa4 NM_001040874.1 13.4 3.1 2.8
MIR1974 MicroRNA 1974 NR_031738.1 12.8 24.1 24.5
RMRP RNA component of mitochondrial RNA processing
endoribonuclease
NR_003051.2 12.1 14.1 15.6
RNA18S5 RNA18S5 RNA, 18S ribosomal 5 NR_003286.1 11.4 11.9 12.6
RNU4-2 RNA, U4 small nuclear 2 NR_003137.2 10.7 5.7 6.3
SCARNA20 Small Cajal body-specific RNA 20 NR_002999.2 7.7 3.2 3.1
LOC441763 Hypothetical Protein LOC441763 XM_930284.1 7.4 5.9 7.2
LOC728688 Ubiquitin-like, containing PHD and RING finger domains XM_001724542.1 6.6 6.1 7.3
VTRNA1-1 Vault RNA 1-1 NR_026703.1 6.5 4.4 4.1
RNU6-1 RNA, U6 small nuclear 1 NR_004394.1 6.3 6.9 7.3
RNU6-15 RNA, U6 small nuclear 15 NR_028372.1 6.3 6.2 7.1
ALB Albumin NM_000477.3 4.9 5.3 5.5
HIST1H4H Histone cluster 1, H4h NM_003543.3 4.9 2.9 2.9
HIST2H4A Histone cluster 2, H4a NM_003548.2 4.6 5.1 4.7
TRK1 Transfer RNA lysine 1 (anticodon UUU) NR_001449.1 4.6 3.5 3.8
SNORD46 Small nucleolar RNA, C/D box 46 NR_000024.2 4.2 3.9 3.8
RNU4ATAC RNA, U4atac small nuclear (U12-dependent splicing) NR_023343.1 4.2 3.7 3.9
KREMEN2 Kringle containing transmembrane protein 2 NM_145348.1 4.1 2.9 2.8
RNU11 RNA, U11 small nuclear NR_004407.1 3.8 2.8 2.9
SNORA57 Small nucleolar RNA, H/ACA box 57 NR_004390.1 3.8 4.9 5.2
RPPH1 Ribonuclease P RNA component H1 NR_002312.1 3.7 2.7 3.1
SCARNA13 Small Cajal body-specific RNA 13 NR_003002.1 3.7 4.3 4.9
RPL12P6 Ribosomal protein L12 pseudogene 6 XR_016704.2 3.5 2.4 4.1
LOC389787 Tumor protein, translationally-controlled 1 pseudogene XM_497072.2 3.4 3.1 2.1
RPL10L Ribosomal protein L10-like NM_080746.2 3.3 3.6 3.7
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Table 3 List of genes that statistically distinguish the hyperthermic response of three breast cancer lines from the
mammary epithelial cells in the H’ vs H analysis (Continued)
SNORA7B Small nucleolar RNA, H/ACA box 7B NR_002992.2 3.2 4.8 5.1
LOC100132673 Ribosomal protein S2 pseudogene 28 XR_039018.1 3.1 2.3 2.6
RNY4 RNA, Ro-associated Y4 NR_004393.1 3.1 5.5 4.7
HOXB6 Homeobox B6 NM_018952.4 2.9 4.2 4.1
HIST1H4K Histone cluster 1, H4k NM_003541.2 2.9 3.2 3.3
SNORA12 Small nucleolar RNA, H/ACA box 12 NR_002954.1 2.9 2.4 2.3
LOC643031 MT-ND5 pseudogene 10 XM_926402.1 2.8 2.9 3.8
HIST2H4B Histone cluster 2, H4b NM_001034077.4 2.7 2.8 2.9
HIST2H3D Histone cluster 2, H3d NM_001123375.1 2.3 3.7 3.9
HIST1H2AC Histone cluster 1, H2ac NM_003512.3 2.3 2.9 2.7
EGR1 Early growth response 1 NM_001964.2 2.3 2.8 2.4
SNORA63 Small nucleolar RNA, H/ACA box 63 NR_002586.1 2.3 7.8 7.3
SNORD13 Small nucleolar RNA, C/D box 13 NR_003041.1 2.3 5.6 5.7
RNY1 RNA, Ro-associated Y1 NR_004391.1 2.1 4.4 4.1
HIST1H2AM Histone cluster 1, H2am NM_003514.2 2.1 3.1 3.5
MARCH7 Membrane-associated ring finger 7,
E3 ubiquitin protein ligase
NM_022826.2 −2.0 −2.3 −2.3
GPBP1 GC-rich promoter binding protein 1 NM_022913.1 −2.0 −3.4 −2.9
RAB11FIP1 RAB11 family interacting protein 1 (class I) NM_001002814.1 −2.0 −2.0 −2.8
CEBPG CCAAT/enhancer binding protein (C/EBP), gamma NM_001806.2 −2.0 −2.0 −2.5
ZWILCH Zwilch kinetochore protein NR_003105.1 −2.0 −2.7 −2.6
DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 NM_006773.3 −2.0 −2.6 −2.7
PTP4A1 Protein tyrosine phosphatase type IVA, member 1 NM_003463.3 −2.0 −2.9 −2.4
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked NM_001356.3 −2.0 −2.6 −2.3
CTCF CCCTC-binding factor (zinc finger protein) NM_006565.2 −2.0 −2.6 −2.3
SKAP2 src kinase associated phosphoprotein 2 NM_003930.3 −2.0 −2.3 −2.2
ANO6 Anoctamin 6 NM_001025356.1 −2.0 −2.3 −2.3
PPAT Phosphoribosyl pyrophosphate amidotransferase NM_002703.3 −2.0 −2.1 −2.3
USP34 Ubiquitin specific peptidase 34 NM_014709.3 −2.0 −2.1 −2.0
LHFPL2 Lipoma HMGIC fusion partner-like 2 NM_005779.1 −2.1 −2.1 −2.1
KIAA1147 KIAA1147 NM_001080392.1 −2.1 −2.1 −2.3
KIAA2010 SMEK homolog 1, suppressor of mek1 (Dictyostelium) NM_032560.3 −2.1 −3.6 −3.0
DYRK1A Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A NM_130438.1 −2.1 −2.5 −2.3
RBBP8 Retinoblastoma binding protein 8 NM_203291.1 −2.1 −2.6 −2.4
ANKIB1 Ankyrin repeat and IBR domain containing 1 NM_019004.1 −2.1 −2.5 −2.5
C12orf32 RAD9-HUS1-RAD1 interacting nuclear orphan 1 NM_031465.2 −2.1 −2.1 −2.1
FNIP1 Folliculin interacting protein 1 NM_001008738.2 −2.1 −2.0 −2.1
NAE1 NEDD8 activating enzyme E1 subunit 1 NM_001018160.1 −2.2 −2.0 −2.3
RSBN1 Round spermatid basic protein 1 NM_018364.3 −2.2 −2.0 −2.3
SUPT16H Suppressor of Ty 16 homolog (S. cerevisiae) NM_007192.2 −2.2 −2.1 −2.2
TMED10 Transmembrane emp24-like trafficking protein 10 (yeast) NM_006827.5 −2.2 −3.6 −2.9
PPP1CB Protein phosphatase 1, catalytic subunit, beta isozyme NM_206876.1 −2.2 −2.4 −2.7
ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 NM_015161.1 −2.2 −2.8 −2.7
ASNSD1 Asparagine synthetase domain containing 1 NM_019048.1 −2.2 −2.9 −2.5
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NRBF2P4 Nuclear receptor binding factor 2 pseudogene 4 XM_001127763.1 −2.2 −2.6 −2.4
TTC37 Tetratricopeptide repeat domain 37 NM_014639.2 −2.2 −2.6 −2.2
DICER1 Dicer 1, ribonuclease type III NM_030621.2 −2.2 −2.6 −2.3
UBE2G1 Ubiquitin-conjugating enzyme E2G 1 NM_003342.4 −2.2 −2.5 −2.4
LRPPRC Leucine-rich pentatricopeptide repeat containing NM_133259.2 −2.2 −2.4 −2.2
OTUD4 OTU domain containing 4 NM_199324.1 −2.2 −2.3 −2.2
FUBP3 Far upstream element (FUSE) binding protein 3 NM_003934.1 −2.2 −2.3 −2.2
FAM175B Family with sequence similarity 175, member B NM_032182.3 −2.2 −2.1 −2.1
DDX50 DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 NM_024045.1 −2.2 −2.0 −2.1
PIGA Phosphatidylinositol glycan anchor biosynthesis, class A NM_020473.2 −2.2 −2.0 −2.2
FAM168B Family with sequence similarity 168, member B NM_001009993.2 −2.3 −2.0 −2.0
FBXO11 F-box protein 11 NM_025133.3 −2.3 −2.1 −2.5
SLC25A24 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24 NM_013386.3 −2.3 −3.4 −2.5
NCKAP1 NCK-associated protein 1 NM_013436.3 −2.3 −3.3 −2.7
FBXW11 F-box and WD repeat domain containing 11 NM_033645.2 −2.3 −2.5 −2.7
SLC30A9 Solute carrier family 30 (zinc transporter), member 9 NM_006345.3 −2.3 −2.0 −2.7
ATAD2 ATPase family, AAA domain containing 2 NM_014109.2 −2.3 −2.8 −2.0
CSNK1A1 Casein kinase 1, alpha 1 NM_001025105.1 −2.3 −2.5 −2.2
CHUK Conserved helix-loop-helix ubiquitous kinase NM_001278.3 −2.3 −2.2 −2.3
ATP6V1C1 ATPase, H + transporting, lysosomal 42 kDa, V1 subunit C1 NM_001695.4 −2.3 −2.1 −2.4
CUL2 Cullin 2 NM_003591.2 −2.3 −2.2 −2.1
BRMS1L Breast cancer metastasis-suppressor 1-like NM_032352.3 −2.3 −2.1 −2.0
UBQLN1 Ubiquilin 1 NM_013438.3 −2.3 −2.1 −2.1
OPA1 Optic atrophy 1 (autosomal dominant) NM_015560.1 −2.4 −2.7 −2.6
EFR3A EFR3 homolog A (S. cerevisiae) NM_015137.3 −2.4 −2.3 −3.2
BAT2D1 Proline-rich coiled-coil 2C NM_015172.3 −2.4 −2.5 −2.1
OSBPL9 Oxysterol binding protein-like 9 NM_148906.1 −2.4 −2.6 −2.5
CDR2 Cerebellar degeneration-related protein 2, 62 kDa NM_001802.1 −2.4 −2.3 −2.2
KPNA4 Karyopherin alpha 4 (importin alpha 3) NM_002268.3 −2.4 −2.2 −2.4
ARL1 ADP-ribosylation factor-like 1 NM_001177.3 −2.4 −2.2 −2.3
DHX32 DEAH (Asp-Glu-Ala-His) box polypeptide 32 NM_018180.2 −2.4 −2.1 −2.3
RIOK3 RIO kinase 3 NM_003831.3 −2.4 −2.0 −2.1
C5orf51 Chromosome 5 open reading frame 51 NM_175921.4 −2.5 −2.8 −2.6
TJP1 Tight junction protein 1 NM_003257.3 −2.5 −2.4 −2.2
CSNK1G3 Casein kinase 1, gamma 3 NM_001031812.2 −2.5 −2.4 −2.3
PREI3 MOB family member 4, phocein NM_199482.1 −2.5 −2.4 −2.4
KIAA0494 EF-hand calcium binding domain 14 NM_014774.1 −2.5 −2.3 −2.4
PRKRIR Protein-kinase, interferon-inducible double stranded
RNA dependent inhibitor, repressor of (P58 repressor)
NM_004705.2 −2.5 −2.7 −3.0
LOC644363 LOC644363 XR_016912.2 −2.5 −2.6 −2.9
DCP2 DCP2 decapping enzyme homolog (S. cerevisiae) NM_152624.4 −2.5 −2.5 −3.0
ROD1 Polypyrimidine tract binding protein 3 NM_005156.4 −2.5 −2.9 −3.2
CRK v-crk sarcoma virus CT10 oncogene homolog (avian) NM_016823.2 −2.5 −3.3 −2.8
PRKAR1A Protein kinase, cAMP-dependent, regulatory, type I, alpha NM_002734.3 −2.5 −2.6 −2.4
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GPSM2 G-protein signaling modulator 2 NM_013296.3 −2.5 −2.2 −2.3
API5 Apoptosis inhibitor 5 NM_006595.2 −2.5 −2.1 −2.5
CRKL v-crk sarcoma virus CT10 oncogene homolog (avian)-like NM_005207.2 −2.5 −2.0 −2.6
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase NM_005188.2 −2.5 −2.0 −2.2
SMG1 smg-1 homolog, phosphatidylinositol 3-kinase-related kinase interferon NM_015092.3 −2.6 −2.9 −2.6
IRF2BP2 Regulatory factor 2 binding protein 2 NM_182972.2 −2.6 −2.7 −2.7
CNOT6 CCR4-NOT transcription complex, subunit 6 NM_015455.3 −2.6 −2.7 −2.6
THUMPD1 THUMP domain containing 1 NM_017736.3 −2.6 −2.6 −2.5
BMI1 BMI1 polycomb ring finger oncogene NM_005180.5 −2.6 −2.4 −2.7
CDC2L6 Cyclin-dependent kinase 19 NM_015076.3 −2.6 −2.4 −2.8
TULP4 Tubby like protein 4 NM_001007466.1 −2.6 −2.3 −2.6
LARP4B La ribonucleoprotein domain family, member 4B NM_015155.1 −2.6 −2.3 −2.3
HECTD1 HECT domain containing E3 ubiquitin protein ligase 1 NM_015382.1 −2.6 −2.6 −2.4
CPSF2 Cleavage and polyadenylation specific factor 2, 100 kDa NM_017437.1 −2.6 −2.8 −2.6
PDS5A PDS5, regulator of cohesion maintenance, homolog A (S. cerevisiae) NM_015200.1 −2.6 −2.6 −2.9
RIPK1 Receptor (TNFRSF)-interacting serine-threonine kinase 1 NM_003804.3 −2.6 −2.1 −2.4
DCAF6 DDB1 and CUL4 associated factor 6 NM_001017977.1 −2.6 −2.1 −2.4
KIAA1429 KIAA1429 NM_015496.3 −2.6 −2.0 −2.3
RUNX1 Runt-related transcription factor 1 NM_001754.3 −2.6 −2.1 −2.2
CEP135 Centrosomal protein 135 kDa NM_025009.3 −2.6 −2.0 −2.2
MBNL1 Muscleblind-like splicing regulator 1 NM_207296.1 −2.6 −2.5 −2.2
RBPJ Recombination signal binding protein for immunoglobulin kappa J region NM_203284.1 −2.6 −2.4 −2.0
USP16 Ubiquitin specific peptidase 16 NM_006447.2 −2.6 −2.2 −2.1
TOMM20 Translocase of outer mitochondrial membrane 20 homolog (yeast) NM_014765.1 −2.7 −2.3 −2.5
MTX3 Metaxin 3 NM_001010891.3 −2.7 −2.7 −2.6
RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 NM_213589.1 −2.7 −2.6 −2.5
PHF20L1 PHD finger protein 20-like 1 NM_016018.4 −2.7 −2.6 −2.7
UBP1 Upstream binding protein 1 (LBP-1a) NM_014517.3 −2.7 −2.5 −2.6
GBE1 Glucan (1,4-alpha-), branching enzyme 1 NM_000158.2 −2.7 −2.4 −2.3
CUL4B Cullin 4B NM_001079872.1 −2.7 −2.4 −2.4
PAPOLA Poly(A) polymerase alpha NM_001037281.1 −2.7 −2.4 −2.9
RNMT RNA (guanine-7-) methyltransferase NM_003799.1 −2.7 −2.1 −2.4
FBXO34 F-box protein 34 NM_017943.2 −2.7 −2.3 −2.1
DOCK7 Dedicator of cytokinesis 7 NM_033407.2 −2.7 −2.3 −2.1
BTBD3 BTB (POZ) domain containing 3 NM_014962.2 −2.7 −2.2 −2.1
C6orf130 O-acyl-ADP-ribose deacylase 1 NM_145063.2 −2.8 −2.3 −2.1
MRPL35 Mitochondrial ribosomal protein L35 NM_016622.2 −2.8 −2.2 −2.2
PUM2 Pumilio homolog 2 (Drosophila) NM_015317.1 −2.8 −2.8 −2.8
NUDT21 Nudix (nucleoside diphosphate linked moiety X)-type motif 21 NM_007006.2 −2.8 −2.7 −2.3
ICK Intestinal cell (MAK-like) kinase NM_016513.3 −2.8 −2.7 −2.5
RBM17 RNA binding motif protein 17 NM_032905.3 −2.8 −2.4 −2.1
RMI1 RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae) NM_024945.2 −2.9 −2.4 −2.1
MAP2K4 Mitogen-activated protein kinase kinase 4 NM_003010.2 −2.9 −2.8 −2.8
G3BP2 GTPase activating protein (SH3 domain) binding protein 2 NM_203504.1 −2.9 −2.5 −2.5
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NAMPT Nicotinamide phosphoribosyltransferase NM_005746.2 −2.9 −2.7 −2.1
BEND7 BEN domain containing 7 NM_001100912.1 −2.9 −2.2 −2.1
FEZ2 Fasciculation and elongation protein zeta 2 (zygin II) NM_005102.2 −3.0 −2.2 −2.2
ARL4A ADP-ribosylation factor-like 4A NM_001037164.1 −3.0 −2.4 −2.2
SOCS4 Suppressor of cytokine signaling 4 NM_080867.2 −3.0 −3.0 −2.6
STAG2 Stromal antigen 2 NM_001042750.1 −3.0 −2.9 −2.5
C14orf32 Mitogen-activated protein kinase 1 interacting protein 1-like NM_144578.2 −3.0 −2.9 −2.9
PPP3CB Protein phosphatase 3, catalytic subunit, beta isozyme NM_021132.1 −3.0 −2.4 −2.6
RBM25 RNA binding motif protein 25 NM_021239.1 −3.0 −2.4 −2.5
ERI1 Exoribonuclease 1 NM_153332.3 −3.0 −2.0 −2.3
NRD1 Nardilysin (N-arginine dibasic convertase) NM_002525.1 −3.0 −2.4 −2.1
E2F3 E2F transcription factor 3 NM_001949.2 −3.0 −2.0 −2.0
ANKRD28 Ankyrin repeat domain 28 NM_015199.2 −3.1 −2.3 −2.2
ZAK Sterile alpha motif and leucine zipper containing kinase AZK NM_133646.2 −3.1 −3.1 −3.4
HNRPR Heterogeneous nuclear ribonucleoprotein R NM_005826.2 −3.1 −2.9 −2.1
TMEM123 Transmembrane protein 123 NM_052932.2 −3.1 −2.8 −2.3
FAM178A Family with sequence similarity 178, member A NM_018121.3 −3.1 −2.7 −2.6
EML4 Echinoderm microtubule associated protein like 4 NM_019063.2 −3.1 −2.6 −2.6
FOXJ3 Forkhead box J3 NM_014947.3 −3.1 −2.5 −2.5
NT5DC3 5'-nucleotidase domain containing 3 NM_016575.1 −3.1 −2.3 −2.6
LPP LIM domain containing preferred translocation partner in lipoma NM_005578.2 −3.1 −2.2 −3.5
RND3 Rho family GTPase 3 NM_005168.3 −3.1 −2.0 −2.2
WDR36 WD repeat domain 36 NM_139281.2 −3.1 −2.0 −2.2
CDCA1 NUF2, NDC80 kinetochore complex component NM_145697.1 −3.1 −2.5 −2.0
PRSS23 Protease, serine, 23 NM_007173.4 −3.2 −2.3 −2.0
ERCC6L Excision repair cross-complementing rodent repair deficiency,
complementation group 6-like
NM_017669.2 −3.2 −2.3 −2.0
FAM122B Family with sequence similarity 122B NM_032448.1 −3.3 −2.5 −2.0
CKAP5 Cytoskeleton associated protein 5 NM_001008938.1 −3.3 −2.2 −2.1
CGGBP1 CGG triplet repeat binding protein 1 NM_001008390.1 −3.3 −2.8 −3.5
TBL1XR1 Transducin (beta)-like 1 X-linked receptor 1 NM_024665.3 −3.3 −3.1 −2.7
LOC644799 LOC644799 XM_934554.1 −3.3 −3.0 −2.5
DCK Deoxycytidine kinase NM_000788.1 −3.3 −2.8 −2.2
SERBP1 SERPINE1 mRNA binding protein 1 NM_030666.2 −3.3 −2.1 −3.3
PPP1CC Protein phosphatase 1, catalytic subunit, gamma isozyme NM_002710.1 −3.3 −2.2 −2.1
KIF5B Kinesin family member 5B NM_004521.1 −3.4 −4.1 −3.3
AFF4 AF4/FMR2 family, member 4 NM_014423.3 −3.4 −3.6 −3.5
MPP5 Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) NM_022474.2 −3.4 −3.1 −2.7
IPO5 Importin 5 NM_002271.4 −3.4 −2.6 −2.2
HNRNPR Heterogeneous nuclear ribonucleoprotein R NM_005826.3 −3.4 −2.6 −2.3
CP110 Centriolar coiled coil protein 110 kDa NM_014711.3 −3.4 −2.5 −2.5
FEM1C fem-1 homolog c (C. elegans) NM_020177.2 −3.4 −2.4 −2.5
PHTF1 Putative homeodomain transcription factor 1 NM_006608.1 −3.4 −2.3 −2.1
RAD51AP1 RAD51 associated protein 1 NM_006479.3 −3.4 −2.2 −2.0
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MAPRE1 Microtubule-associated protein, RP/EB family, member 1 NM_012325.1 −3.4 −2.1 −2.1
TMPO Thymopoietin NM_003276.1 −3.5 −3.1 −2.3
LACTB Lactamase, beta NM_032857.2 −3.5 −2.3 −2.3
DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 NM_014829.2 −3.5 −2.3 −2.4
SPEN Spen homolog, transcriptional regulator (Drosophila) NM_015001.2 −3.5 −2.0 −2.7
TMEM19 Transmembrane protein 19 NM_018279.3 −3.5 −2.1 −2.0
CBFB Core-binding factor, beta subunit NM_001755.2 −3.5 −2.2 −2.2
IPO8 Importin 8 NM_006390.2 −3.5 −2.2 −2.1
WT1 Wilms tumor 1 NM_024426.3 −3.5 −2.4 −2.1
CKAP2 Cytoskeleton associated protein 2 NM_001098525.1 −3.6 −3.0 −2.4
WEE1 WEE1 homolog (S. pombe) NM_003390.2 −3.6 −2.8 −2.7
PDCD6IP Programmed cell death 6 interacting protein NM_013374.3 −3.6 −2.7 −2.3
ZNF788 Zinc finger family member 788 XR_041527.1 −3.6 −2.6 −2.3
RAP2A RAP2A, member of RAS oncogene family NM_021033.5 −3.6 −2.3 −2.7
MGEA5 Meningioma expressed antigen 5 (hyaluronidase) NM_012215.2 −3.6 −2.1 −2.7
UBE3A Ubiquitin protein ligase E3A NM_000462.2 −3.6 −2.0 −2.8
PLK4 Polo-like kinase 4 NM_014264.3 −3.7 −3.8 −3.2
RP2 Retinitis pigmentosa 2 (X-linked recessive) NM_006915.1 −3.7 −2.9 −2.5
SETD2 SET domain containing 2 NM_014159.4 −3.7 −2.7 −2.8
KLHL5 Kelch-like family member 5 NM_001007075.1 −3.7 −2.4 −2.6
KBTBD2 Kelch repeat and BTB (POZ) domain containing 2 NM_015483.1 −3.7 −3.7 −3.1
USP9X Ubiquitin specific peptidase 9, X-linked NM_001039591.2 −3.8 −2.8 −2.4
RAB23 RAB23, member RAS oncogene family NM_016277.3 −3.8 −2.6 −2.5
DR1 Down-regulator of transcription 1, TBP-binding (negative cofactor 2) NM_001938.2 −3.8 −2.3 −2.2
RAB8B RAB8B, member RAS oncogene family NM_016530.2 −3.8 −2.3 −2.5
ZNF451 Zinc finger protein 451 NM_001031623.2 −3.8 −2.2 −2.4
ZZZ3 Zinc finger, ZZ-type containing 3 NM_015534.4 −3.9 −3.1 −3.3
CDC2 Cyclin-dependent kinase 1 NM_001786.2 −4.0 −2.9 −2.3
ZFP106 Zinc finger protein 106 NM_022473.1 −4.0 −3.0 −2.5
CAB39 Calcium binding protein 39 NM_016289.2 −4.0 −2.0 −3.1
TNPO1 Transportin 1 NM_153188.2 −4.0 −2.9 −2.5
MAP3K4 Mitogen-activated protein kinase kinase kinase 4 NM_005922.2 −4.1 −2.3 −2.7
ECT2 Epithelial cell transforming sequence 2 oncogene NM_018098.4 −4.1 −2.3 −2.0
TMED5 Transmembrane emp24 protein transport domain containing 5 NM_016040.3 −4.1 −2.3 −2.1
SEH1L SEH1-like (S. cerevisiae) NM_001013437.1 −4.1 −2.7 −2.5
NCAPG2 Non-SMC condensin II complex, subunit G2 NM_017760.5 −4.2 −2.7 −2.2
USP1 Ubiquitin specific peptidase 1 NM_001017416.1 −4.2 −2.3 −2.4
OXSR1 Oxidative-stress responsive 1 NM_005109.2 −4.2 −2.3 −2.4
PTPN12 Protein tyrosine phosphatase, non-receptor type 12 NM_002835.2 −4.2 −2.8 −2.8
CMPK1 Cytidine monophosphate (UMP-CMP) kinase 1, cytosolic NM_016308.1 −4.2 −2.5 −2.4
PAFAH1B1 Platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45 kDa) NM_000430.2 −4.3 −3.8 −3.1
PURB Purine-rich element binding protein B NM_033224.3 −4.3 −2.5 −3.5
STK4 Serine/threonine kinase 4 NM_006282.2 −4.3 −2.3 −3.3
KATNAL1 Katanin p60 subunit A-like 1 NM_001014380.1 −4.3 −3.1 −2.9
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NIN Ninein (GSK3B interacting protein) NM_020921.3 −4.3 −2.7 −2.4
LOC283267 Long intergenic non-protein coding RNA 294 NR_015451.1 −4.3 −2.6 −2.6
CCNB1 Cyclin B1 NM_031966.2 −4.3 −2.4 −2.2
YAP1 Yes-associated protein 1 NM_006106.2 −4.3 −2.0 −2.5
XPO1 Exportin 1 (CRM1 homolog, yeast) NM_003400.3 −4.4 −2.9 −2.6
PTPN11 Protein tyrosine phosphatase, non-receptor type 11 NM_002834.3 −4.4 −2.4 −2.5
PHF3 PHD finger protein 3 NM_015153.1 −4.4 −2.2 −2.6
VMA21 Vacuolar H + −ATPase homolog (S. cerevisiae) NM_001017980.2 −4.4 −2.2 −2.3
CHST15 Carbohydrate sulfotransferase 15 NM_015892.2 −4.4 −2.0 −2.5
RUNX2 Runt-related transcription factor 2 NM_001024630.2 −4.5 −2.7 −2.4
KIF14 Kinesin family member 14 NM_014875.1 −4.6 −3.4 −2.2
EHBP1 EH domain binding protein 1 NM_015252.2 −4.6 −2.7 −2.6
NEK2 NIMA-related kinase 2 NM_002497.2 −4.6 −2.7 −2.6
STK38 Serine/threonine kinase 38 NM_007271.2 −4.7 −3.2 −2.4
ZNF22 Zinc finger protein 22 NM_006963.3 −4.7 −3.2 −2.8
SPRY4 Sprouty homolog 4 (Drosophila) NM_030964.2 −4.7 −2.0 −2.1
GMFB Glia maturation factor, beta NM_004124.2 −4.8 −2.2 −3.2
GCNT1 Glucosaminyl (N-acetyl) transferase 1, core 2 NM_001097635.1 −4.8 −3.1 −2.4
HERC4 HECT and RLD domain containing E3 ubiquitin
protein ligase 4
NM_022079.2 −4.8 −3.1 −2.6
PPP4R1 Protein phosphatase 4, regulatory subunit 1 NM_005134.2 −4.8 −2.1 −2.6
SMAD5 SMAD family member 5 NM_005903.5 −4.9 −2.2 −3.2
GNG12 guanine nucleotide binding protein (G protein), gamma 12 NM_018841.4 −4.9 −2.8 −2.1
SMARCA1 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 1
NM_003069.2 −4.9 −2.8 −2.3
DEK DEK oncogene NM_003472.2 −4.9 −2.5 −2.4
FAM107B Family with sequence similarity 107, member B NM_031453.2 −5.1 −3.1 −2.1
SUZ12 Suppressor of zeste 12 homolog (Drosophila) NM_015355.1 −5.1 −2.8 −2.7
OSBPL3 Oxysterol binding protein-like 3 NM_145322.1 −5.1 −2.7 −2.7
UBE3C Ubiquitin protein ligase E3C NM_014671.1 −5.1 −2.7 −2.7
HSDL2 Hydroxysteroid dehydrogenase like 2 NM_032303.3 −5.1 −2.5 −2.5
C14orf106 MIS18 binding protein 1 NM_018353.3 −5.1 −2.3 −2.3
MBP Myelin basic protein NM_001025100.1 −5.1 −2.0 −2.3
GPAM Glycerol-3-phosphate acyltransferase, mitochondrial NM_020918.3 −5.2 −3.1 −2.7
RASA1 RAS p21 protein activator (GTPase activating protein) 1 NM_002890.1 −5.2 −2.9 −3.1
KIF11 Kinesin family member 11 NM_004523.2 −5.2 −3.3 −3.1
FBXO5 F-box protein 5 NM_012177.2 −5.2 −3.1 −2.3
CENPE Centromere protein E, 312 kDa NM_001813.2 −5.2 −2.6 −2.3
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 NM_002577.3 −5.3 −3.3 −3.6
IL7R Interleukin 7 receptor XM_937367.1 −5.3 −2.8 −2.2
ENC1 Ectodermal-neural cortex 1 (with BTB domain) NM_003633.1 −5.3 −2.6 −2.3
SOX9 SRY (sex determining region Y)-box 9 NM_000346.2 −5.3 −2.5 −2.3
ASXL1 Additional sex combs like 1 (Drosophila) (ASXL1), TV1 NM_015338.4 −5.3 −2.0 −2.0
C10orf6 Family with sequence similarity 178, member A NM_018121.2 −5.5 −3.2 −3.4
CEP55 Centrosomal protein 55 kDa NM_018131.3 −5.6 −3.4 −2.6
Amaya et al. BMC Cancer 2014, 14:81 Page 18 of 27
http://www.biomedcentral.com/1471-2407/14/81
Table 3 List of genes that statistically distinguish the hyperthermic response of three breast cancer lines from the
mammary epithelial cells in the H’ vs H analysis (Continued)
NMT2 N-myristoyltransferase 2 NM_004808.2 −5.6 −2.4 −2.0
PPPDE1 Desumoylating isopeptidase 2 NM_016076.3 −5.8 −2.4 −2.9
TGFBR2 Transforming growth factor, beta receptor II (70/80 kDa) NM_001024847.1 −6.0 −2.1 −2.2
MID1 Midline 1 (Opitz/BBB syndrome) NM_033290.2 −6.2 −2.9 −2.1
FNDC3B Fibronectin type III domain containing 3B NM_001135095.1 −6.2 −2.8 −2.6
BIRC2 Baculoviral IAP repeat containing 2 NM_001166.3 −6.2 −2.9 −2.7
FAM3C Family with sequence similarity 3, member C NM_001040020.1 −6.2 −2.4 −2.0
KIF23 Kinesin family member 23 NM_004856.4 −6.3 −3.4 −2.7
CLIC4 Chloride intracellular channel 4 NM_013943.1 −6.3 −3.4 −2.6
PDGFC Platelet derived growth factor C NM_016205.1 −6.4 −2.4 −2.0
PRKCA Protein kinase C, alpha NM_002737.2 −6.7 −2.5 −2.2
NCAPG Non-SMC condensin I complex, subunit G NM_022346.3 −7.1 −2.6 −2.1
CENPF Centromere protein F, 350/400 kDa NM_016343.3 −7.4 −2.9 −2.7
GCNT2 Glucosaminyl (N-acetyl) transferase 2,
I-branching enzyme (I blood group)
NM_001491.2 −7.4 −2.5 −2.5
C14orf135 Pecanex-like 4 (Drosophila) NM_022495.5 −7.5 −2.7 −2.5
PBK PDZ binding kinase NM_018492.2 −7.8 −3.3 −2.4
TOP2A Topoisomerase (DNA) II alpha 170 kDa NM_001067.2 −8.1 −3.8 −2.7
CAV2 Caveolin 2 NM_001233.3 −8.1 −2.3 −2.5
SERTAD2 SERTA domain containing 2 NM_014755.1 −8.3 −3.1 −3.6
ACSL4 Acyl-CoA synthetase long-chain family member 4 NM_004458.1 −8.5 −2.5 −2.5
FAM83D Family with sequence similarity 83, member D NM_030919.2 −9.2 −4.3 −3.8
CDK6 Cyclin-dependent kinase 6 NM_001259.5 −9.4 −3.1 −4.1
FRMD6 FERM domain containing 6 NM_152330.3 −9.5 −3.1 −2.4
SNAPC1 Small nuclear RNA activating complex, polypeptide 1, 43 kDa NM_003082.2 −9.8 −2.3 −2.0
CALD1 Caldesmon 1 NM_033140.2 −9.9 −2.1 −2.5
BCAT1 Branched chain amino-acid transaminase 1, cytosolic NM_005504.4 −10.2 −5.6 −4.2
DLGAP5 Discs, large (Drosophila) homolog-associated protein 5 NM_014750.3 −10.4 −3.1 −2.4
ANLN Anillin, actin binding protein NM_018685.2 −10.9 −3.1 −2.2
TACC1 Transforming, acidic coiled-coil containing protein 1 NM_006283.1 −11.1 −2.7 −2.6
AP1S2 Adaptor-related protein complex 1, sigma 2 subunit NM_003916.3 −11.5 −2.5 −2.1
CTNNAL1 Catenin (cadherin-associated protein), alpha-like 1 NM_003798.2 −13.9 −3.1 −2.1
DCBLD2 Discoidin, CUB and LCCL domain containing 2 NM_080927.3 −14.5 −3.1 −2.6
CAV1 Caveolin 1, caveolae protein, 22 kDa NM_001753.3 −20.1 −3.3 −2.8
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changes were common between one or more of the breast
cancer lines, not a single 2-fold or greater gene expression
change was shared between the mammary epithelial line
and all three breast cancer lines (Figure 1B). This data
strongly suggested that the hyperthermic response of
breast cancer cells is truly distinct from that of mam-
mary epithelial cells. As an independent assessment, we
generated profile plots depicting the changes in normal-
ized intensity values between the four cell lines, revealing
that many of the statistically significant gene expressionalterations we identified were largely shared between
the three breast cancer lines and distinctly unique from
that of the MCF10A line (Figure 1C). Using Metacore
network analysis of the microarray data, we identified
key signaling pathways that were unique to the mam-
mary epithelial line and the three breast cancer lines.
The hyperthermic response of MFC10A was strongly
indicative of statistically significant gene expression al-
terations in a large number of genes involved in cell
cycle regulation, apoptosis, heat shock response, and
DNA damage response, (Figure 2A-D, Table 2) and
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biological pathways were not observed in the three
breast cancer lines. Network analysis indicated that sig-
naling pathways with the highest statistical significance
amongst the three breast cancer lines responding to
hyperthermia (but not in the MCF10A line) included
genes involved in Ras and Rab5A G-protein regulation
(GAPVD1, RASA1, RABEP1, CALM1, GMFB, PTPN11)Figure 4 Interaction network analysis of the differential response of t
strong node centered on mitotic cell cycle progression. The list of 393
following fever range hyperthermia in the H’ vs H comparison were querie
associations derived from previously reported genomic context, high-throu(Figure 2E, Table 2) and survival/apoptosis (MAP2K4,
BIRC2) (Figure 2B, Table 2).
Identification of hyperthermia induced genes that
differentiate the heat shock response of mammary
epithelial cells from that of breast cancer cells
Our previous analysis compared the hyperthermic response
of each individual cell line to its transcriptional expressionhe breast cancer cells to fever range hyperthermia reveals a
genes identified as differentially expressed in the breast cancer lines
d using String 9.05. Lines illustrate known physical and functional
ghput experiments, coexpression analysis, and Pubmed.
Table 4 Top 20 significantly significant GeneGo pathway
maps that are differentially expressed amongst all three
breast cancer cell lines relative to the mammary





Mitotic sister chromatid segregation 1.31e-22
Mitotic spindle organization 4.87e-20
Protein localization to kinetochore 1.54e-19
Chromosome segregation 4.85e-16
Establishment of mitotic spindle orientation 7.53e-16
Mitotic cell cycle 9.66e-16
Homologous chromosome segregation 3.30e-13
Mitotic cell cycle checkpoint 5.99e-12
Anaphase promoting complex-dependent degradation 2.27e-10
Mitotic cell cycle spindle assembly checkpoint 2.03e-09




Mitotic centrosome separation 7.75e-08
Spindle assembly 1.92e-07
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vs H’). Though this analysis provides us with information on
how each individual cell line responds to hyperthermia rela-
tive to its normal growth temperature, it does not provide
absolute comparisons of the transcriptome response of
breast cancer cells relative to mammary epithelial cells fol-
lowing the elevated temperature. To better understand what
provides breast cancer cells the selective disadvantage over
mammary epithelial cells in response to hyperthermia we
must identify those genes that are differentially expressed in
breast cancer cell lines following hyperthermia from those
of the mammary epithelial cell line following hyperthermia.
To perform this analysis, we directly compared the gene ex-
pression changes that occurred for H’ vs H and identified
genes whose expression was truly distinct between the
breast cancer and mammary epithelial cell lines following
hyperthermia.
When comparing H’ (MCF7) vs H we identified 2708
genes whose expression was distinct at statistically sig-
nificant levels (≥2 fold, p < 0.05). H’ vs H comparisons of
the MDA231 and MDA468 lines yielded 919 and 750
significant gene expression changes, respectively. Heat-
map analysis indicated a strong trend in the gene ex-
pression profiles between each of the three breast cancer
lines following hyperthermia (Figure 3A). Using a Venn
diagram that strictly eliminated any genes with less than
a 2-fold expression change (p < 0.05), we compared the
gene expression alterations that were uniquely shared
between all three cancer lines (H’) relative to the mam-
mary epithelial line (H) (Figure 3B). This interpretation
uncovered 393 genes whose 2-fold or greater changes in
gene expression were differentially expressed in common
amongst the three breast cancer lines following mild
hyperthermic shock when compared to MCF10A cells fol-
lowing the same treatment (Table 3). These are the core
genes that differentiate the hyperthermic response of
breast cancer cells from that of mammary epithelial cells.
In these data potentially lay the mechanism that may help
define how mild hyperthermia preferentially selects against
tumor cells.
We performed computational analysis on the 393 genes
using String software to identify interaction networks that
might help reveal functional nodes indicative of the bio-
logical response of these cells to fever range hyperthermia.
Our analysis uncovered a remarkably dense interaction
node centered on genes involved in mitotic progression
(Figure 4). We performed Metacore analysis on the list of
393 genes, confirming that mitotic cell cycle regulatory
networks exclusively dominated the top statistically signifi-
cant pathway maps (Table 4 lists the top 20 identified
networks). Figure 5 illustrates Metacore’s analysis of the
interrelationships of the identified mitotic regulatory genes
including STAG2, NEK2, KPNA4, IPO5, TNPO1, CCNB1,
CDK1, CDK6, NCAPG, NCAPG2, TOP2A, NUF2, CENPE,CENPF, ZWILCH, PDS5A, WEE1, KIF11, CHUK, and
PPP1CB. Of the 393 genes that were differentially
expressed between the breast cancer and mammary epi-
thelial cells following H’ to H analysis, approximately 80%
of the top 60 most upregulated genes were histone
clusters and non-protein coding RNAs such as small
nucleolar-, ribosomal-, and micro-RNAs. These data
cumulatively suggest that the selective disadvantage
that breast cancer lines experience following mild hyper-
thermic shock may be due to an inability to correctly
regulate their core biological processes and mitotic cell
cycle machinery. The differential expression of genes in-
volved in these processes for the H’ vs H analysis is shown
in Figure 6.
Altered expression of mitotic arrest genes differentiates
the hyperthermic response of breast cancer cells from
that of mammary epithelial cells
Our microarray analysis strongly suggests that the inability
of breast cancer cells to regulate their mitotic cell cycle
machinery may be a major contributing factor to their
selective disadvantage following hyperthermia. There-
fore we independently tested the expression levels of a
panel of mitotic regulators that were identified as differ-
entially expressed in the H’ vs H analysis. Quantitative real
time PCR analysis of cDNA collected from the H’ vs H
Figure 5 Interrelationship between the mitotic regulators that differentiate the hyperthermic response of breast cancer cells from
mammary epithelial cells. Metacore analysis of the 393 genes that differentiate the hyperthermic response of breast cancer from mammary
epithelial cells in the H’ vs H comparison identified mitotic cell cycle progression (and 20 associated mitotic regulatory genes) as the primary
differential gene networks. We used Metacore to identify the interrelationship of the known physical and functional associations between these
20 genes (red markers).
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genes with core processes related to mitosis including
KIF11, CDK6, STAG2, NEK2, CHUK, KPNA4, CENPF,
and NCAPG correlated well with our microarray data,
revealing differential expression of these genes for each
cell line in the hyperthermia treatment relative to the
normal temperature (Figure 7A). A comparison of the
qPCR and microarray data for each of these selected
genes for the H’ to H comparisons is depicted in Table 5.
To confirm the hyperthermia-induced mitotic defect in
the breast cancer lines, we subjected all four cell lines to
30 minutes of fever range hyperthermia (H and H’) or nor-
mal control temperature (C and C’) and collected the cells
after 24 hours for cell cycle analysis using flow cytometry.
The cells were collected 24 hrs after treatment as this is
sufficient time to see the phenotypic effects on the cell
cycle that would be induced by altered RNA expression.
Propidium iodide staining of cells from each condition
clearly revealed that a G2/M phase accumulation as a
common event across all three breast cancer lines follow-
ing hyperthermia even after 24 hours following the treat-
ment, but did not occur in the mammary epithelial lines
(Figure 7B). Collectively, these data provide evidence to
suggest that the selective disadvantage of breast cancercells in response to hyperthermia could be due, in part,
to altered regulation of mitotic machinery following heat
shock.
Discussion
While hyperthermic treatment of tumors has been utilized
since the time of the ancient Greeks and modern medicine
has implemented hyperthermia as an adjuvant treat-
ment in various settings, use of this technique has been
marred with limitations including the inability to target
heat to the tumor without collateral damage to the neigh-
boring cells, homogenous heat dispersion throughout the
entire tumor, and intrinsic problems with targeting un-
detectable micrometastases. In recent years, advances in
nanoparticle-enabled thermal therapy hold the promise to
overcome many of these issues, thus a strong interest in
treatment of tumors with hyperthermia has been renewed.
While it has been established for decades that normal tis-
sues exhibit enhanced thermotolerance relative to cancer
cells [1,2], the mechanisms controlling this are largely un-
known. Studies on the heat shock response of cancer cells
have revealed changes in apoptosis, cell cycle regulation,
and cell structure/maintenance [3], yet very little has been
















































































Figure 6 Gene expression changes in histones, non-protein coding
RNAs, and mitotic regulators differentiate the hyperthermic
response of breast cancer cells from mammary epithelial cells.
Heatmap depicting the two-fold or greater changes in RNA
expression levels (p < 0.05) for histone, non-protein coding RNA, and
mitotic regulatory genes in the H’ vs H comparison (red = overexpressed,
green = underexpressed).
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Thus it is currently unknown at the molecular level how
thermotolerance is maintained in normal cells, but lost or
deregulated in cancer cells. To address this, we utilized a
genomics approach to address two areas: 1) identify the
global transcriptional response to hyperthermia of a panel
of breast cancer and mammary epithelial cells using a C vs
H and C’ vs H’ analysis and 2) compare the hyperthermia-
induced changes in global gene expression patterns of the
breast cancer cell lines to the mammary epithelial cells
using a H’ vs H analysis. As a result of these studies, we
identified several gene networks that reflect the hyperther-
mic response of breast cancer and mammary epithelial
cells (including cell cycle, heat shock, survival/apoptosis,
DNA damage and Rab/Ran regulation) and that clearly dif-
ferentiate the response of breast cancer cells from that ofmammary epithelial cells (including mitotic regulation and
expression of histone and non-protein coding RNAs).
Evaluation of the hyperthermic response of breast cancer
and mammary epithelial cells
C vs H and C’ vs H’ comparative analysis of the gene ex-
pression profiles of each cell line revealed that the mam-
mary epithelial cells responded to increased temperature
distinctly from the breast cancer lines, with altered regula-
tion of gene networks controlling DNA damage response,
cell cycle progression, apoptosis, and heat shock character-
izing the mammary epithelial cell response. In contrast, the
three breast cancer lines commonly altered gene networks
encoding Rab and Ran G-protein regulators in response to
hyperthermia.
Arguably the most studied response of cells to hyperther-
mia is that of heat shock protein activation and expression
and one might guess that heatshock-protein mediated
responses are likely responsible for the selective disad-
vantage of solid tumors to fever range hyperthermia.
Numerous cell stresses have been shown to induce heat
shock proteins, which act as molecular chaperones inside
cells to modulate thermotolerance and protect cells from
stress-induced death [27-29]. MCF10A cells exhibited sig-
nificantly increased expression of HSP90AA1, CARHSP1,
HSPA12A and decreased expression of HSPB1, HSPBL2,
HSPA6, and HSPA7 (C vs H), while the three breast can-
cer lines showed no significant 2-fold or greater alter-
ations in the expression of these genes (C’ vs H’). Despite
this finding, we provide evidence that suggests the ability
of mammary epithelial cells to properly modulate their
heat shock response does not contribute to the selective
disadvantage of breast cancer cells to hyperthermia. For in-
stance, comparison of heat shock protein expression in the
H’ vs H analysis revealed no significant difference in the
relative abundance of these heat shock protein genes re-
gardless of the cell type. As elevated expression of heat
shock proteins has been observed in various types of can-
cers [30-32], hyperthermic shock may simply bring the
heat shock protein expression in MCF10A cells to the
baseline levels in the breast cancer lines.
Hyperthermia has long been known as an effective
radio- and chemo-sensitizing agent and it would be an
attractive hypothesis that hyperthermia may impart a
selective disadvantage to breast cancer cells via upregu-
lation of DNA damage or reduction in its repair. Indeed,
hyperthermia has been shown to induce chromosomal
damage during S-phase [33] and inhibit homologous re-
combination repair via a heat shock protein/Brca1/2
pathway [34-36]. Furthermore, hyperthermia induces
signaling pathways that overlap with those activated by
ionizing radiation-induced DNA damage including histone
H2Ax phosphorylation and enhanced ataxia-telangiectasia
mutated protein (ATM) activity [37]. Analysis of C vs H
AB
Figure 7 Biological confirmation of gene expression analysis. (A) qPCR analysis measuring the fold change of mitotic regulators following
hyperthermia treatment. RQ values are represented as the hyperthermia-induced change in gene expression for each gene relative to the expression of the
same gene in the normal temperature condition (RQ= 1). The data shown are the median of at least 3 replicates, plus or minus the standard deviation, and
presented in log scale. (B) The panel of mammary epithelial and breast cancer cells were grown under standard growth conditions or treated with 30 minutes
fever range hyperthermic shock. Cells were harvested after 24 hours and cell cycle analysis was performed using flow cytometric detection of propidium
iodide intensity.
Amaya et al. BMC Cancer 2014, 14:81 Page 24 of 27
http://www.biomedcentral.com/1471-2407/14/81and C’ vs H’ revealed a number of genes involved in DNA
damage response whose expression was altered in the
MCF10A cells, and similar changes were not observed in
the three breast cancer lines. Despite this, no statistically
significant changes in gene expression for these genes
were observed in our H’ vs H comparison, suggesting that
(similar to the heat shock proteins) this pathway may notclearly distinguish the selective disadvantage of breast can-
cer cells to hyperthermia.
Gene networks that distinguish the hyperthermic response
of breast cancer cells from mammary epithelial cells
As our initial analysis compared only the heat shock
response of each individual cell line relative to its
Table 5 qPCR and microarray expression data for
selected cell cycle genes in the H’ vs H comparison
Gene Symbol MCF7 MBA231 MBA468
qPCR Array qPCR Array qPCR Array
KIF11 −1.5 −5.2 −2.6 −3.3 −1.2 −3.1
CDK6 −2.4 −9.4 −1.7 −3.1 −3.0 −4.1
STAG2 −2.7 −3.0 −3.2 −2.9 −2.0 −2.5
NEK2 −4.7 −4.6 −1.7 −2.7 −2.8 −2.6
CHUK −4.3 −2.3 −1.4 −2.2 −1.3 −2.3
KPNA4 −1.7 −2.4 −7.3 −2.2 −1.6 −2.4
CENPF −2.9 −7.4 −183 −2.9 −5.4 −2.7
NCAPG −3.5 −4.2 −9.3 −2.7 −1.9 −2.2
p ≤ 0.05 for all values via Student’s t-test.
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we extended our analysis by directly comparing the tran-
scriptional response of the H’ vs H treatments to identify
the unique gene networks that clearly differentiate the
gene expression changes unique to the breast cancer cells
following heat treatment. This comparative analysis identi-
fied cell cycle networks preferentially involved in mitotic
progression as well as large scale changes in the expres-
sion of histones and non-protein coding RNAs as the
major distinctions between the hyperthermic responses
between the breast cancer lines and the MCF10A cells.
80% of the top 60 genes commonly expressed at higher
levels in the three breast cancer lines following heat shock
relative to the mammary epithelial line following heat
shock were histones and non-coding RNA. This effect was
due primarily to decreased expression of these genes in
the MCF10A cells with no change or only a small upregu-
lation in expression in the breast cancer lines, suggesting
that mammary epithelial cells are repressing many of their
core processes (chromatin condensation, transcription,
translation, etc.) following hyperthermic shock, while the
breast cancer cells may continue performing these pro-
cesses as normal. Similar findings have been reported fol-
lowing other cellular stresses whereby oxidative damage
significantly decreases the expression of histones and ribo-
somal proteins [38]. In addition to histone gene expression,
heat shock induces an array of chromatin post-translational
modifications. For instance, HSP70 has been shown to en-
hance the phosphorylation of histone H3 following heat
shock [39], and histone variant H3.3 has been shown to
stimulate heat shock induced HSP70 transcription [40],
suggesting that heat shock response and histone activity are
tightly regulated.
Our data revealed that a number of small nucleolar
RNAs, which play key roles in ribosomal biosynthesis,
were differentially regulated between the mammary epi-
thelial and breast cancer cells following hyperthermia.
Several small nucleolar RNAs are reportedly criticalmediators of oxidative stress and their overexpression has
been associated with reduced resistance to oxidative stress
[41,42]. Small nucleolar RNAs have been shown to bind
to the mature RNA of heat shock cognate protein
(HSC70) [43] and inhibition of Hsp90 prevents the accu-
mulation of U3 and U4 small nuclear ribonucleoproteins
via a process that involves Pih1/Nop17 and R2Tp com-
plexes [44-46].
Changes in cell cycle progression (particularly mitotic
catastrophe) have been repeatedly shown to characterize
the hyperthermic response of numerous cell types
[47-49], though it is largely unstudied as to how cell
cycle changes differ between normal and tumor cell lines
following this treatment. Major distinctions in cell cycle
networks involved in mitotic progression clearly distin-
guished the H’ vs H analysis of our data. The genes that
were differentially expressed at statistically significant
levels included those involved in spindle assembly and
chromosome separation, chromosome condensation in
prometaphase, metaphase checkpoint, sister chromatid
cohesion, and initiation of mitosis. Our confirmatory ex-
periments using flow cytometry further revealed that
hyperthermia treated breast cancer cells stalled in the
G2/M phase of the cell cycle within 24 hours post-
treatment, while the cell cycle profiles of heat-shocked
mammary epithelial cells were similar to those grown at
normal temperatures. Interestingly, it has been shown
that cells vary in their susceptibility to heat in accord-
ance to their phase in the cell cycle, with the highest
heat sensitivity observed during mitosis due to damage
to the mitotic apparatus, leading to inefficient mitosis and
polyploidy. M- and S-phase arrested cells show increased
susceptibility to heat-induced damage, while G1-phase
cells are relatively heat resistance [50-53].
This study has been the first to shed light on the com-
parisons of transcriptome-level fever range hyperthermic
responses of mammary epithelial cells to breast cancer
cells. While this data points to a number of areas that po-
tentially contribute to the selective advantage of normal
breast epithelium over its malignant counterparts follow-
ing hyperthermia, our studies were simplistic in that they
utilized a cell culture monolayer system solely consisting
of cells derived from normal or tumor breast tissue. We
have gained solid insight into the responses of these par-
ticular cell types to fever range hyperthermia, however a
tumor is a very complex entity. For instance, solid tumors
are not only composed of the tumor cells, but also consist
of endothelial, fibroblast, and immune cells which will
each respond to hyperthermia in their own fashion and
potentially affect the response of the tumor as a whole.
Moreover, heterogenous heat distribution and dissipation
due to a faulty tumor vascular system may induce uneven
heating in the tumor itself, thus affecting some areas dis-
tinctly and differentially altering the tumor’s response to
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address these issues.
Conclusion
Collectively, our data suggest that fever range hyperther-
mia affects breast cancer cells distinctly from mammary
epithelial cells. These differences are largely attributed to
alterations in the expression of genes involved in mitotic
cell cycle progression, histones, and non-coding RNAs.
Considering the hyperthermia induced G2/M cell cycle
defects observed in the breast cancer cells but not the
mammary epithelial cells, these data pose the question as
to whether hyperthermia may function in a synergistic
manner when combined with drugs that specifically target
mitosis such as taxols and vinca alkaloid derivatives.
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